Jacqueline M. Greer

1.7k citations

33 papers · 1.2k indexed · h-index 15

Molecular Biology top 10%
Hematology top 2%
Oncology top 10%
Public Health, Environmental and Occupational Health top 10%
Genetics top 10%

Co-authors: Judith E. Karp Ivana Gojo James R. Wright Lawrence E. Morris Michael L. Tidwell James A. Zwiebel Steven D. Gore Mark J. Levis
Topics: Acute Myeloid Leukemia Research (29 papers)Acute Lymphoblastic Leukemia research (13 papers)Chronic Lymphocytic Leukemia Research (7 papers)
Cited by: Hematology Oncology Genetics
Journals: Journal of Clinical Oncology Blood Clinical Cancer Research
Partner nations: United States

In The Last Decade

Jacqueline M. Greer

33 papers receiving 1.2k citations

Peers

Countries citing papers authored by Jacqueline M. Greer

Since Specialization

Citations

This map shows the geographic impact of Jacqueline M. Greer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacqueline M. Greer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacqueline M. Greer more than expected).

Fields of papers citing papers by Jacqueline M. Greer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacqueline M. Greer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacqueline M. Greer. The network helps show where Jacqueline M. Greer may publish in the future.

Co-authorship network of co-authors of Jacqueline M. Greer

This figure shows the co-authorship network connecting the top 25 collaborators of Jacqueline M. Greer. A scholar is included among the top collaborators of Jacqueline M. Greer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacqueline M. Greer. Jacqueline M. Greer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Population pharmacokinetics and exposure–response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias 2018 ·Cancer Chemotherapy and Pharmacology ·(unknown),(unknown),(unknown),Mathangi Gopalakrishnan,Ivana Gojo,Judith E. Karp,Jacqueline M. Greer,Alice Chen,Richard Piekarz,Brian F. Kiesel,Jogarao Gobburu,Michelle A. Rudek,Jan H. Beumer	5
2	Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure‐FLT3 Relationship 2018 ·Clinical and Translational Science ·Tao Liu,Vijay Ivaturi,(unknown),Jogarao Gobburu,Jacqueline M. Greer,James R. Wright,B. Douglas Smith,Keith W. Pratz,Michelle A. Rudek,(unknown)	17
3	Exposure–Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients 2017 ·Clinical Cancer Research ·(unknown),Vijay Ivaturi,Jogarao Gobburu,Jacqueline M. Greer,L. Austin Doyle,James R. Wright,Judith E. Karp,Michelle A. Rudek	9
4	Exposure–Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies 2017 ·Clinical Cancer Research ·(unknown),Mathangi Gopalakrishnan,Jogarao Gobburu,Jiuping Ji,Jacqueline M. Greer,Richard Piekarz,Judith E. Karp,Keith W. Pratz,Michelle A. Rudek	4
5	Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with haematological malignancies 2017 ·British Journal of Clinical Pharmacology ·(unknown),Mathangi Gopalakrishnan,Jogarao Gobburu,Jacqueline M. Greer,Richard Piekarz,Judith E. Karp,Keith W. Pratz,Michelle A. Rudek	6
6	Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside with and without the CHK1 Inhibitor MK-8876 in Adults with Relapsed and Refractory Acute Myelogenous Leukemia 2015 ·Blood ·Jonathan Webster,Raoul Tibes,Amanda L. Blackford,Lawrence E. Morris,Mrinal M. Patnaik,Lihua Wang,(unknown),Jacqueline M. Greer,Mark R. Litzow,Larry M. Karnitz,Gary L. Rosner,Austin Doyle,Scott H. Kaufmann,Judith E. Karp,B. Douglas Smith	2
7	A Phase I Study Of The Histone Deacetylase Inhibitor Entinostat Plus Clofarabine For Philadelphia Chromosome Negative, Poor Risk (Newly Diagnosed Older Adults or Adults with Relapsed and Refractory Disease) Acute Lymphoblastic Leukemia Or Bilineage/Biphenotypic Leukemia 2013 ·Blood ·Hetty E. Carraway,Judith E. Karp,Ivana Gojo,Keith W. Pratz,Nilanjan Ghosh,Steven D. Gore,Margaret M. Showel,Mark J. Levis,Benjamin D. Smith,Jacqueline M. Greer,James G. Herman,Lia Gore,Min-Jung Lee,Sunmin Lee,Peter Ordentlich,Richard Piekarz,Jane B. Trepel	1
8	Phase 1 dose‐escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias 2012 ·British Journal of Haematology ·Amer M. Zeidan,Rebecca M. Ricklis,Hetty E. Carraway,(unknown),Jacqueline M. Greer,Benjamin D. Smith,Mark J. Levis,Michael A. McDevitt,Keith W. Pratz,Margaret M. Showel,Douglas E. Gladstone,Steven D. Gore,Judith E. Karp	6
9	Risk assessment in human immunodeficiency virus-associated acute myeloid leukemia 2011 ·Leukemia & lymphoma ·Michael Evans,Anthony D. Sung,Ivana Gojo,Michael Tidwell,Jacqueline M. Greer,Mark J. Levis,Judith E. Karp,Maria R. Baer	4
10	Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia 2011 ·Haematologica ·Scott H. Kaufmann,Judith E. Karp,(unknown),(unknown),W. Michael Hogan,David P. Steensma,Karen S. Flatten,D A Loegering,P A Schneider,Kevin Peterson,Matthew J. Maurer,B. Douglas Smith,Jacqueline M. Greer,Ye Chen,Joel M. Reid,S. Percy Ivy,Matthew M. Ames,Alex A. Adjei,Charles Erlichman,Larry M. Karnitz	30
11	Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias 2011 ·Blood ·Judith E. Karp,Benjamin D. Smith,Linda Resar,Jacqueline M. Greer,Amanda L. Blackford,Ming Zhao,(unknown),(unknown),Mark J. Levis,Steven D. Gore,Biju Joseph,Hetty E. Carraway,Michael A. McDevitt,(unknown),(unknown),Janet Briel,L. Austin Doyle,James R. Wright,Michelle A. Rudek	67
12	Phase I Dose-Escalation Study of SCH 900776 in Combination with Cytarabine (Ara-C) in Patients with Acute Leukemia 2011 ·Blood ·B M Thomas,Scott H. Kaufmann,Jacqueline M. Greer,Steven D. Gore,Keith W. Pratz,B. Douglas Smith,(unknown),(unknown),Jo Ann Horowitz,Judith E. Karp	4
13	Randomized Phase II Study of Two Schedules of Flavopiridol (Alvocidib, F) Given as Timed Sequential Therapy (TST) Wtih Ara-C and Mitoxantrone (FLAM) for Adults with Newly Diagnosed, Poor-Risk Acute Myelogenous Leukemia (AML) 2010 ·Blood ·Judith E. Karp,John M. Pagel,B. Douglas Smith,Jacqueline M. Greer,(unknown),Kelly M. Smith,Kathleen Shannon Dorcy,James R. Wright,L. Austin Doyle,Elizabeth Garrett‐Mayer,Elihu H. Estey	2
14	Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia 2009 ·Leukemia Research ·Judith E. Karp,Amanda L. Blackford,B. Douglas Smith,(unknown),(unknown),Javier Bolaños‐Meade,Jacqueline M. Greer,Hetty E. Carraway,Steven D. Gore,Richard J. Jones,Mark J. Levis,Michael A. McDevitt,L. Austin Doyle,James R. Wright	54
15	Human Immunodeficiency Virus (HIV)-Associated Acute Myeloid Leukemia (AML) in the Era of Highly Active Antiretroviral Therapy (HAART): High Complete Remission Rate, but Poor Tolerance of Consolidation Therapy and Short Disease-Free Survival. 2009 ·Blood ·Michael Evans,Anthony D. Sung,Ivana Gojo,Michael L. Tidwell,Jacqueline M. Greer,Mark J. Levis,Judith E. Karp,Maria R. Baer	1
16	Phase I and pharmacokinetic study of Triapine®, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies 2007 ·Leukemia Research ·Ivana Gojo,Michael L. Tidwell,Jacqueline M. Greer,Naoko Takebe,Karen Seiter,(unknown),Bonny Johnson,Mario Sznol,Judith E. Karp	65
17	A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders 2007 ·Leukemia Research ·Judith E. Karp,Francis J. Giles,Ivana Gojo,Lawrence E. Morris,Jacqueline M. Greer,Bonny Johnson,Mya Thein,Mario Sznol,Jennifer A. Low	92
18	A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias 2007 ·Blood ·Judith E. Karp,Rebecca M. Ricklis,Kumudha Balakrishnan,Janet Briel,Jacqueline M. Greer,Steven D. Gore,B. Douglas Smith,Michael A. McDevitt,Hetty E. Carraway,Mark J. Levis,Varsha Gandhi	59
19	Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias 2006 ·Blood ·Ivana Gojo,Anchalee Jiemjit,Jane B. Trepel,Alex Sparreboom,William D. Figg,Sandra Rollins,Michael L. Tidwell,Jacqueline M. Greer,Eun Joo Chung,Min-Jung Lee,Steven D. Gore,Edward A. Sausville,James A. Zwiebel,Judith E. Karp	231
20	Tipifarnib (Zarnestra, R115777) as Maintenance Therapy for Adults in Complete Remission (CR) Following Induction and Consolidation Therapies for Poor-Risk Acute Myelogenous Leukemia (AML): A Phase II Trial. 2005 ·Blood ·Judith E. Karp,Ivana Gojo,Jacqueline M. Greer,Benjamin D. Smith,(unknown),(unknown),Steven D. Gore,Lawrence E. Morris,Alain Thibault,Mary Ellen Rybak,James R. Wright	4

About Jacqueline M. Greer

Jacqueline M. Greer is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health, having authored 33 papers that have together received 1.2k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (29 papers), Acute Lymphoblastic Leukemia research (13 papers) and Chronic Lymphocytic Leukemia Research (7 papers). The work is most often cited by research in Hematology (614 citations), Oncology (418 citations) and Genetics (151 citations). Jacqueline M. Greer has collaborated with scholars based in United States. Frequent co-authors include Judith E. Karp, Ivana Gojo, James R. Wright, Lawrence E. Morris, Michael L. Tidwell, James A. Zwiebel, Steven D. Gore, Mark J. Levis, Janet Briel and B. Douglas Smith. Their work appears in journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact